Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PARG | Q86W56 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 3/20 | 0.31 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.30 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2284096 | 0.74 | MPO (0.57) | CYP3A4HPGDMPO | |
| SCHEMBL2454380 | 0.72 | TLR7 (0.47) | MTNR1AMTNR1BGAAMAPK1ALDH1A1 | |
| SCHEMBL2454484 | 0.72 | MTNR1A (0.41) | MTNR1AMTNR1BGAAMAPK1ALDH1A1 | |
| SCHEMBL2454465 | 0.70 | MTNR1A (0.55) | MTNR1AMTNR1BGAAMAPK1ALDH1A1 | |
| SCHEMBL1958327 | 0.69 | MTNR1A (0.52) | MTNR1AMTNR1BGAAMAPK1ALDH1A1 | |
| SCHEMBL1960192 | 0.69 | TSHR (0.75) | MTNR1AMTNR1BALDH1A1CYP3A4HPGD | |
| SCHEMBL2455424 | 0.69 | MTNR1A (0.49) | MTNR1AMTNR1BGAAMAPK1ALDH1A1 | |
| SCHEMBL1958450 | 0.68 | KMT2A (0.56) | MTNR1AMTNR1BGAAMAPK1ALDH1A1 | |
| SCHEMBL1958423 | 0.68 | GAA (0.59) | MTNR1AMTNR1BGAAMAPK1ALDH1A1 | |
| SCHEMBL2456190 | 0.68 | PKM (0.58) | MTNR1AMTNR1BGAAMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010535-B1 | THIOXANTHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF MPO | ASTRAZENECA AB (SE) | 2012-07-11 | — | — | EP | disclosed |
| US-8026244-B2 | Thioxanthine derivatives and their use as inhibitors of MPO | ASTRAZENECA AB (SE) | 2011-09-27 | — | — | US | disclosed |
| US-20090149475-A1 | Thioxanthine Derivatives and Their Use as Inhibitors of MPO | ASTRAZENECA AB (SE) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149475-A1 | Thioxanthine Derivatives and Their Use as Inhibitors of MPO | MPO, XDH, EPX | MTNR1A 234/4885MTNR1B 450/4885GAA 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.